NASDAQ:NDRA ENDRA Life Sciences Q2 2025 Earnings Results & Report $4.95 -0.09 (-1.71%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more. ENDRA Life Sciences beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$1.71 versus the -$2.27 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call4:00 PM ET ENDRA Life Sciences EPS ResultsActual EPS-$1.71Consensus EPS -$2.27Beat/MissBeat by +$0.56One Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersENDRA Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsENDRA Life Sciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ENDRA Life Sciences Q2 2025 Earnings FAQ Did ENDRA Life Sciences beat earnings estimates for Q2 2025? ENDRA Life Sciences (NASDAQ:NDRA) reported earnings of -$1.71 per share for Q2 2025, beating the consensus estimate of -$2.27. The report was announced on Thursday, August 14, 2025. When is ENDRA Life Sciences' next earnings date? ENDRA Life Sciences' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for ENDRA Life Sciences on the company's earnings history page. ENDRA Life Sciences Earnings HeadlinesENDRA Shares Rise 12% As Q2 Loss Swings To Profit; Advances Noble Africa MergerSeptember 4, 2026 | rttnews.comENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 17, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 14 at 1:00 AM | Porter & Company (Ad)ASP Isotopes to Host Investor Meetings at Citi’s 2026 Natural Resources ConferenceAugust 5, 2026 | quiverquant.comQASP Isotopes Announces Capital Markets Day in London on September 8, 2026July 28, 2026 | quiverquant.comQENDRA Life Sciences (NDRA) Gets a Buy from AscendiantJuly 25, 2026 | theglobeandmail.comSee More ENDRA Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email. Email Address About ENDRA Life SciencesENDRA Life Sciences (NASDAQ:NDRA) Corp. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic imaging systems. The company’s primary technology is Thermo-Acoustic Enhanced UltraSound (TAEUS), a platform designed to expand the capabilities of conventional ultrasound by using radiofrequency energy and ultrasound imaging to characterize tissue properties. ENDRA is initially focused on applying TAEUS to the assessment of liver fat, including fatty liver disease. Its system is intended to provide quantitative information about hepatic steatosis and potentially other tissue characteristics without requiring an invasive biopsy or the use of more costly imaging modalities. The technology is designed to work with existing ultrasound equipment, which could support broader adoption in clinical settings. Based in Ann Arbor, Michigan, ENDRA has worked with medical-device and imaging-industry partners to advance the development and validation of its technology. TAEUS remains a medical-device development program and may require additional regulatory clearances and clinical validation before broader commercial use. The company is led by Chief Executive Officer Francois Michelon.View ENDRA Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
